Cover Image
市場調查報告書

慢性背部痛:開發平台評估

Chronic Back Pain - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 251626
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
慢性背部痛:開發平台評估 Chronic Back Pain - Pipeline Review, H2 2014
出版日期: 2014年08月25日 內容資訊: 英文 67 Pages
簡介

所謂慢性背部痛一般是指發生在脊樑骨的肌肉、神經、骨、關節、其他結構的長期性背痛。造成的原因幾乎都是肌肉緊張、受傷、脊椎變形、全身性疾病,或也有可能是風濕疾病造成。治療法有使用止痛劑和非類固醇系的抗發炎性藥物

本報告網羅全球慢性背部痛治療藥的開發平台資訊,為您提供目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及開發中的產品檢討等。

目錄

簡介

  • 分析範圍

慢性背部痛概要

治療藥的開發

  • 慢性背部痛轉動開發中產品:概要
  • 慢性背部痛轉動開發中產品:比較分析

慢性背部痛:開發中的治療藥:各企業

慢性背部痛:開發中的治療藥:大學·研究機關別

慢性背部痛:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

慢性背部痛:開發中的產品:各企業

慢性背部痛:開發中的產品:大學·研究機關別

慢性背部痛:治療藥的開發企業

  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
  • Collegium Pharmaceutical, Inc.
  • Grunenthal GmbH
  • Endo Pharmaceuticals Inc.
  • Adynxx, Inc.
  • Akron Molecules GmbH

慢性背部痛:治療藥的評估

  • 單劑治療藥
  • 組合
  • 標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • hydrocodone bitartrate ER
  • buprenorphine hydrochloride
  • cycloserine
  • oxycodone ER
  • (oxycodone hydrochloride + naltrexone hydrochloride) Extended Release
  • cebranopadol
  • AKR-202
  • AKR-203
  • ASP-7962
  • AYX-2
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5402IDB

Summary

Global Markets Direct's, 'Chronic Back Pain - Pipeline Review, H2 2014', provides an overview of the Chronic Back Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Back Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Chronic Back Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Chronic Back Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Chronic Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Chronic Back Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Chronic Back Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Chronic Back Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chronic Back Pain Overview
  • Therapeutics Development
    • Pipeline Products for Chronic Back Pain - Overview
    • Pipeline Products for Chronic Back Pain - Comparative Analysis
  • Chronic Back Pain - Therapeutics under Development by Companies
  • Chronic Back Pain - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Chronic Back Pain - Products under Development by Companies
  • Chronic Back Pain - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Limited
    • Impax Laboratories, Inc.
    • Collegium Pharmaceutical, Inc.
    • Grunenthal GmbH
    • Endo Pharmaceuticals Inc.
    • Adynxx, Inc.
  • Chronic Back Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • hydrocodone bitartrate ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buprenorphine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • oxycodone ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (oxycodone hydrochloride + naltrexone hydrochloride) ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bupivacaine Patch - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cebranopadol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-7962 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BCIBUBP-005 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AYX-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Chronic Back Pain - Recent Pipeline Updates
  • Chronic Back Pain - Dormant Projects
  • Chronic Back Pain - Discontinued Products
  • Chronic Back Pain - Product Development Milestones
    • Featured News & Press Releases
      • May 01, 2014: ALO-02 Demonstrates Significant Difference In Pain Scores In Chronic Low Back Pain Patients And Lower Abuse Potential Compared To Immediate-Release Oxycodone In Recreational Opioid Users
      • Apr 02, 2014: Collegium Pharmaceutical Announces Positive Topline Results of Clinical Study Evaluating the Effect of Crushing Oxycodone DETERx Compared with OxyContin
      • Mar 19, 2014: Collegium Pharmaceutical Announces Allowance of New Claims Covering DETERx, an Abuse-Deterrent, Extended-Release, Technology Platform
      • Feb 04, 2014: Collegium Pharmaceutical Announces Completion of Enrollment in Pivotal Phase 3 Clinical Study for Oxycodone DETERx, its Lead Abuse-Deterrent Development Program
      • Oct 17, 2013: Collegium Pharmaceutical Announces Issuance of U.S. Patent and Allowance of New Claims Covering Oxycodone DETERx, an Abuse-Deterrent, Extended-Release Opioid Product
      • Oct 18, 2012: Collegium Pharma Announces Poster Presentation On Oxycodone DETERx At 2012 American Association Of Pharmaceutical Scientists Annual Meeting
      • Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity For Cymbalta
      • Feb 03, 2010: Eli Lilly Reports Cymbalta Significantly Reduced Chronic Low Back Pain In A New Study
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chronic Back Pain, H2 2014
  • Number of Products under Development for Chronic Back Pain - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Late Stage Development, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Chronic Back Pain - Pipeline by Astellas Pharma Inc., H2 2014
  • Chronic Back Pain - Pipeline by Pfizer Inc., H2 2014
  • Chronic Back Pain - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014
  • Chronic Back Pain - Pipeline by Impax Laboratories, Inc., H2 2014
  • Chronic Back Pain - Pipeline by Collegium Pharmaceutical, Inc., H2 2014
  • Chronic Back Pain - Pipeline by Grunenthal GmbH, H2 2014
  • Chronic Back Pain - Pipeline by Endo Pharmaceuticals Inc., H2 2014
  • Chronic Back Pain - Pipeline by Adynxx, Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Assessment by Combination Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Chronic Back Pain Therapeutics - Recent Pipeline Updates, H2 2014
  • Chronic Back Pain - Dormant Projects, H2 2014
  • Chronic Back Pain - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Chronic Back Pain, H2 2014
  • Number of Products under Development for Chronic Back Pain - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Target, H2 2014
  • Number of Products by Stage and Top 10 Target, H2 2014
  • Number of Products by Top 10 Mechanism of Action, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H2 2014
  • Number of Products by Top 10 Route of Administration, H2 2014
  • Number of Products by Stage and Top 10 Route of Administration, H2 2014
  • Number of Products by Top 10 Molecule Type, H2 2014
  • Number of Products by Stage and Top 10 Molecule Type, H2 2014
Back to Top